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Abstract
Background: Failure of circulating monocytes for adequate cytokine production is a trait of sepsis-induced
immunosuppression; however, its duration and association with final outcome are poorly understood.
Methods: We conducted a substudy of a large randomised clinical trial. Peripheral blood mononuclear cells
(PBMCs) were isolated within the first 24 h from the onset of systemic inflammatory response syndrome in 95
patients with microbiologically confirmed or clinically suspected gram-negative infections. Isolation was
repeated on days 3, 7 and 10. PBMCs were stimulated for cytokine production. The study endpoints were the
differences between survivors and non-survivors, the persistence of immunosuppression, and determination of
admission clinical signs that can lead to early identification of the likelihood of immunosuppression.
Results: PBMCs of survivors produced significantly greater concentrations of tumour necrosis factor-α (TNF-α),
interleukin (IL)-6, IL-8, IL-10, interferon-γ and granulocyte-macrophage colony-stimulating factor after day 3.
Using ROC analysis, we found that TNF-α production less than 250 pg/ml after lipopolysaccharide stimulation
on day 3 could discriminate patients from healthy control subjects; this was associated with a 5.18 OR of
having an unfavourable outcome (p = 0.046). This trait persisted as long as day 10. Logistic regression analysis
showed that cardiovascular failure on admission was the only independent predictor of defective TNF-α
production on day 3.
Conclusions: Defective TNF-α production is a major trait of sepsis-induced immunosuppression. It is associated
with significant risk for unfavourable outcome and persists until day 10. Cardiovascular failure on admission is
predictive of defective TNF-α production during follow-up.
Trial registration: ClinicalTrials.gov identifier: NCT01223690. Registered on 18 October 2010.
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Background
Sepsis is the leading cause of death in critically ill pa-
tients. Mortality can reach up to 70% of patients with
septic shock and up to 80% of patients with multiple
organ dysfunction [1]. This great mortality reflects our
poor understanding of sepsis for recognition and
management as well as of the mechanisms of its
pathogenesis and pathophysiology. Although tradition-
ally conceived of as an exaggerated reaction of the
host to a microbial insult, one current suggestion of
the immunobiology of sepsis is that, inside the septic
host, pro-inflammatory and anti-inflammatory phe-
nomena co-exist. The phenomena may involve both
hyper-production of pro-inflammatory cytokines by
the innate immune system and impaired innate and
adaptive immune responses [2]. Impaired immune re-
sponses are characterised by enhanced apoptosis and dys-
function of lymphocytes, impaired phagocyte functions
and decreased ex vivo cytokine production [2–4].
Early patient death may result from exaggerated pro-
inflammatory responses [2]. However, late death may be
related to a late anti-inflammatory phase sometimes
called sepsis-induced immunosuppression. In their study,
Boomer et al. explored the function of splenocytes iso-
lated from early cadavers of severe sepsis and compared
them with those from brain-dead subjects with multiple
injuries. A clear-cut down-regulation of both innate and
adaptive immune responses was found, leading to the as-
sumption that sepsis-induced immunosuppression is the
driver towards unfavourable outcome [5].
The findings of the study by Boomer et al. [5] gener-
ated some important questions:
a. How is cytokine production associated with final
outcome?
b. How long does down-regulation of sepsis last?
c. Which clinical signs on admission can help
discriminate the patient who is entering into the
immunosuppression stage?
A proper answer to these questions can lead to appro-
priate application of drugs with the aim of reversing im-
munosuppression of sepsis. In the present study, we used
serial stimulation of circulating mononuclear cells during
patient follow-up to seek answers to these questions.
Methods
Study design
A prospective, randomised clinical trial (ClinicalTrials.gov
identifier NCT01223690) was conducted during the
period from July 2007 to April 2011 in six departments in
Greece to assess the efficacy and safety of intravenous
clarithromycin over placebo for patients with microbio-
logically documented gram-negative infections or with
infections at high clinical risk of being of gram-negative
origin [6]. During this trial, peripheral blood mononuclear
cells (PBMCs) were isolated at serial time intervals for
cytokine stimulation from a subgroup of patients, and
because all-cause mortality was similar in placebo- and
clarithromycin-treated patients, results were analysed
together. The subgroup study design was approved by
the ethics committee of Attikon University Hospital
(license 6/18-05-2011), and written informed consent
was obtained from participants’ first-degree relatives.
Inclusion criteria for this subgroup of patients were (a)
age 18 years or older; (b) written informed consent pro-
vided by first-degree relatives; (c) presence of at least
two signs of the systemic inflammatory response syn-
drome (SIRS); (d) presence of acute pyelonephritis, acute
intra-abdominal infection or primary bacteraemia caused
by gram-negative bacteria; and (e) start of blood sam-
pling within the first 24 h from the onset of signs of
SIRS. Exclusion criteria were (a) neutropenia due to
causes other than SIRS, defined as an absolute number
of neutrophils less than 1000/mm3; (b) diagnosis of HIV
infection; and (c) corticosteroid treatment over the last
30 days in doses greater than 0.4 mg/kg prednisone or
equivalent.
Definitions of acute pyelonephritis, acute intra-abdominal
infections, primary gram-negative bacteraemia and organ
failure have been published [6]. The following data
were recorded for every patient for 28 days: age, sex,
previous medical history, vital signs, clinical signs, type
of infection, type of failing organ, microbiology, labora-
tory findings, Acute Physiology and Chronic Health
Evaluation (APACHE) II score, Sequential Organ Fail-
ure Assessment (SOFA) score and final outcome. A
retrospective evaluation of these patients showed that
they all met the new Sepsis-3 definitions of admission
SOFA score greater than or equal to 2 for patients ad-
mitted at the emergency department or an increase of
admission SOFA score greater than or equal to 2 for
patients developing sepsis after hospital admission [7].
Cardiovascular (CV) failure in patients was defined as
any persisting systolic blood pressure below 90 mmHg
despite restoration of negative fluid balance that neces-
sitated the administration of vasopressors. A retro-
spective evaluation of patients with CV failure showed
that they all met the new Sepsis-3 definition of septic
shock [7].
Laboratory investigation
All laboratory investigation was run in the central la-
boratory of the 4th Department of Internal Medicine at
Attikon University Hospital, Athens, Greece. The time
interval from blood sampling until processing was a
maximum of 1 h. Twenty millilitres of heparinised blood
was collected after venepuncture of one forearm vein
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under aseptic conditions during the first 24 h from the
onset of signs of SIRS (day 1) and repeated on days 3, 7
and 10. PBMCs were separated after gradient centrifuga-
tion of the blood over Ficoll-Hypaque density gradient
(Biochrom, Berlin, Germany). After three washings in
ice-cold PBS, pH 7.2 (Biochrom), PBMCs were counted
using a Neubauer plate with trypan blue exclusion of
dead cells. PBMCs were then stimulated in duplicate at
a density of 5 × 106 cells/ml at 37 °C in a 5% CO2 at-
mosphere in RPMI 1640 medium enriched with 2 mM
of L-glutamine, 100 U/ml penicillin G, 100 mg/ml gen-
tamicin and 10 mM pyruvate with or without 10 ng/ml
lipopolysaccharide (LPS) derived from Escherichia coli
O55:B5 (Sigma-Aldrich, St. Louis, MO, USA), and
5 μg/ml Pam3Cys-SKKK (EMC Microcollections,
Tübingen, Germany). After incubation for 24 or 48 h,
plates were centrifuged at 800 × g for 7 minutes, and
the supernatants were collected and stored at −70 °C
until assayed. Cytokines were measured with a Bio-Plex
Pro Human Cytokine Panel on a Bio-Rad Luminex 200
suspension array system (Bio-Rad Laboratories,
Hercules, CA, USA). The measurements were carried
out according to the manufacturer’s instructions. All
samples were measured in duplicate. Every plate had its
own standard curve built from data also measured in
duplicate. The cytokines used were tumour necrosis
factor-α (TNF-α), interleukin (IL)-6 and IL-8 with
supernatants coming from the 24-h incubation of the
plates, as well as IL-4, IL-10, IL-12, interferon-γ (IFN-γ)
and granulocyte-macrophage colony-stimulating factor
(GM-CSF) using supernatants coming from the 48-h in-
cubation of the plates. The lower limit of detection was
0.5 pg/ml (Additional file 1: Table S1). PBMCs were also
isolated from 16 healthy individuals during the 2007–2011
period and stimulated as described above in the absence
and presence of LPS. TNF-α was measured as described
above to be used as control measurements.
Statistical analysis
Results were expressed as mean ± SE. Patients were di-
vided into survivors and non-survivors on the basis of
their 28-day outcome. Comparison of each cytokine be-
tween healthy control subjects and patients as well as
between survivors and non-survivors was done using the
Mann-Whitney U test. ROC curve analysis was done to
identify TNF-α production on day 3 that could signifi-
cantly differentiate between patients and healthy control
subjects. Using this ROC curve, a cut-off cytokine con-
centration with more than 80% sensitivity for this dis-
crimination was defined. Patients above this cut-off
were considered to have adequate TNF-α production by
circulating PBMCs on day 3; those below this cut-off
were considered to have defective TNF-α production by
circulating PBMCs on day 3. ORs and 95% CIs for
death between patients with adequate and defective
TNF-α production on day 3 were determined using
Mantel-Haenszel statistics. In order to identify which
patients’ characteristics at admission might be predict-
ive of defective TNF-α production on day 3, admission
characteristics of patients with adequate and defective
TNF-α production on day 3 were compared. Compari-
sons were done with Student’s t test for quantitative
variables and the chi-square test for qualitative vari-
ables. A step-wise forward logistic regression analysis
was conducted with defective TNF-α production on day
3 as the dependent variable; admission characteristics
Fig. 1 Study flowchart. SIRS Systemic inflammatory response syndrome
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with differences at a p value below 0.10 were entered
into the equation as independent variables; and ORs
and 95% CIs were determined. Any p value after adjust-
ment for multiple comparisons according to the
method of Bonferroni was considered significant.
Results
From among the total enrolled patients in the clinical
trial, 95 patients participated in the substudy. The study
flowchart is presented in Fig. 1, and the demographic
and clinical characteristics of enrolled patients are dis-
played in Table 1.
Patients were divided into survivors and non-survivors
on the basis of their 28-day outcome. Figure 2 shows the
production of cytokines from PBMCs of survivors and
non-survivors on admission day 1 and on serial days 3, 7
and 10 after stimulation with LPS. Cytokines in superna-
tants of medium-treated cells were below the limit of
detection. Although cytokine production by PBMCs
after LPS stimulation was similar for survivors and non-
survivors on day 1 with the exception of IL-10, PBMCs
of survivors produced significantly greater concentra-
tions of TNF-α, IL-4, IL-6, IL-8, IL-10, IFN-γ and GM-
CSF than PBMCs of non-survivors starting on day 3 and
mainly shown on day 7. The respective increase after
Pam3Cys stimulation was shown for a lower number of
cytokines, mainly TNF-α and IL-10 (Fig. 3).
These findings led us to hypothesise that survival is as-
sociated with improved cytokine production for TNF-α
because TNF-α was the only cytokine that was produced
early from PBMCs of survivors after stimulation with
both stimuli used. TNF-α production by PBMCs of pa-
tients was significantly lower than that by PBMCs of
healthy control subjects during all days of follow-up
when PBMCs were stimulated with LPS; this was not
the case when PBMCs were stimulated with Pam3Cys,
where significant differences ceased to exist after day 3
(Fig. 4a). This made us consider that LPS is a more sen-
sitive stimulus to indicate sepsis-induced immunosup-
pression, which lasted until day 10. When separate
comparisons were done between TNF-α produced by
PBMCs of healthy control subjects and by survivors and
non-survivors of sepsis, production of TNF-α was sig-
nificantly lower in both survivors and non-survivors on
days 3, 7 and 10 when LPS was used as a stimulus; this
was not the case when Pam3Cys was used as a stimulus
(Additional file 2: Table S2).
Next, we designed a ROC curve to discriminate TNF-
α production by PBMCs after LPS stimulation on day 3
between patients and healthy volunteers. Generated
ROC curves for TNF-α production after LPS stimula-
tion provided a statistically significant AUC (Fig. 4b).
Co-ordinate points of the ROC curve showed that
TNF-α production after stimulation with LPS less than
250 pg/ml could discriminate patients from healthy vol-
unteers with 47.7% sensitivity, 81.3% specificity, 93.5%
positive predictive value and 22.0% negative predictive
value. Among the 88 patients surviving on day 3, de-
fective TNF-α production less than 250 pg/ml was
found in 42; 8 (19.0%) of them died, as opposed to 2
(4.3%) of 46 patients in whom TNF-α was above
250 pg/ml (p = 0.043). The OR for death with defective
production of TNF-α by PBMCs after stimulation with
Table 1 Demographic and clinical characteristics of the 95
patients enrolled in the study
Characteristics Data
Males/females, n (%) 52 (54.7%)/43 (45.3%)
Age, years, mean ± SD 68.8 ± 17.0
APACHE II score, mean ± SD 13.83 ± 7.86
PaO2/FiO2, mmHg, mean ± SD 307.6 ± 129.4
White blood cells, count/mm3, mean ± SD 14,735.0 ± 7717.0
C-reactive protein, mg/L mean ± SD 137.2 ± 97.3
Type of infection
Acute pyelonephritis, n (%) 45 (47.4%)
Acute intra-abdominal infection, n (%) 31 (32.6%)
Primary gram-negative bacteraemia, n (%) 19 (20.0%)
Failing organs on enrolment, n (%) 25 (26.3%)
Acute respiratory distress syndrome, n (%) 16 (16.8%)
Acute coagulopathy 13 (13.7%)
Acute kidney injury 12 (12.6%)
Cardiovascular failure 12 (12.6%)
Isolated pathogens in blood and/or urine, n (%)
Escherichia coli 25 (26.3%)
Klebsiella pneumoniae 8 (8.4%)
Proteus mirabilis 5 (5.3%)
Pseudomonas aeruginosa 3 (3.2%)
Acinetobacter baumannii 3 (3.2%)
Other gram-negative bacteria 8 (8.4%)
Co-existing disorders, n (%)
Type 2 diabetes mellitus 29 (30.5%)
Solid tumour malignancy 22 (23.2%)
Chronic renal disease 17 (17.9%)
Chronic obstructive pulmonary disease 15 (15.8%)
Chronic heart failure 9 (9.5%)
Predisposing factors, n (%)
Cerebral stroke 14 (14.7%)
Nephrolithiasis 11 (11.6%)
Gallstones 12 (12.6%)
Multiple injuries 3 (3.2%)
APACHE Acute Physiology and Chronic Health Evaluation, PaO2/FiO2 Ratio of
partial pressure arterial oxygen and fraction of inspired oxygen
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LPS was 5.18 (95% CI 1.03–25.97, p = 0.046); this was
also shown after survival analysis (Fig. 4c).
These findings drive the concept that defective pro-
duction of TNF-α by PBMCs on day 3 may be a marker
of sepsis-induced immunosuppression and generate a
key question: Can clinical signs of a patient on admis-
sion guide the prediction of the level of TNF-α produc-
tion by PBMCs on day 3? To answer this question,
univariate analysis was performed using demographic
and clinical characteristics of patients with TNF-α pro-
duction greater than 250 pg/ml and TNF-α production
less than or equal to 250 pg/ml from circulating PBMCs
after LPS stimulation on day 3 (Table 2). Differences
with p values less than 0.100 were found for APACHE II
score, sex, acute coagulopathy and CV failure. Sex, acute
coagulopathy and CV failure were entered into the equa-
tion of the step-wise logistic regression analysis as inde-
pendent variables. APACHE II was not entered into the
Fig. 2 Cytokine production after stimulation with bacterial endotoxin. Cytokine production from medium-stimulated cells was below the limit of
detection. White bars represent survivors and black bars non-survivors after 28 days of follow-up. p Values indicate statistically significant differences
between survivors and non-survivors at the indicated time intervals. Non-significant differences are now shown. GM-CSF Granulocyte-macrophage
colony-stimulating factor, IFN-γ Interferon-γ, IL Interleukin, TNF-α Tumour necrosis factor-α
Antonakos et al. Critical Care  (2017) 21:48 Page 5 of 10
equation, because blood pressure is one of the APACHE
II components. This analysis revealed that CV failure
was the only risk factor associated with defective pro-
duction of TNF-α on day 3 (Table 3).
Discussion
The present study shows that defective cytokine pro-
duction from circulating PBMCs following a severe
gram-negative infection is a major trait of sepsis-
induced immunosuppression. Defective TNF-α produc-
tion after stimulation with LPS is the most susceptible
trait of this process and remains as late as day 10,
whereas defective TNF-α production induced by stimu-
lation with Pam3Cys is restored by day 7. Defective
TNF-α production after stimulation with LPS is associ-
ated with unfavourable outcome. CV failure on the first
Fig. 3 Cytokine production after stimulation with Pam3Cys. Cytokine production from medium-stimulated cells was below the limit of detection.
White bars represent survivors and black bars non-survivors after 28 days of follow-up. p Values indicate statistically significant differences between
survivors and non-survivors at the indicated time intervals. Non-significant differences are now shown. GM-CSF Granulocyte-macrophage
colony-stimulating factor, IFN-γ Interferon-γ, IL Interleukin, TNF-α Tumour necrosis factor-α
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day is a predictive sign of the persistence of defective
TNF-α production on day 3.
Although traditionally conceived of as a regulator of
an exaggerated immune response, it is now broadly ac-
cepted that immunosuppression may exist right from
the onset of sepsis [2]. This is not the first study showing
an association of cytokine production by circulating
PBMCs over the course of sepsis with final outcome.
Several years ago, Munoz et al. [8] showed a profound
inhibition of circulating monocytes for the production of
TNF-α and IL-1β. This was most pronounced when LPS
was used as a stimulus in patients experiencing gram-
negative infections. A rebound of this phenomenon was
associated with favourable outcome. We enrolled a lar-
ger population than that in the study of Munoz et al. [8];
our studied population had gram-negative bacteria infec-
tions, whereas theirs had infections of mixed causality;
and we elaborated significant clinical variables that can
predict from the first day the likelihood of incapacity of
PBMCs for the production of TNF-α. The correlation of
diminished TNF-α production and shock was demon-
strated in 2001 by de Werra et al. [9]. They compared
TNF-α production and CD14 expression on monocytes
among patients with severe sepsis, septic shock or car-
diogenic shock as well as in healthy volunteers. Their re-
sults demonstrated a defective response of monocytes
and lower TNF-α levels in both patients with sepsis and
patients with cardiogenic shock compared with healthy
control subjects.
In a recent publication, Santos et al. [10] stimulated
whole blood from 34 patients with sepsis with LPS,
Pseudomonas aeruginosa and Staphylococcus aureus. By
flow cytometric analysis, they showed that the intracellu-
lar levels of IL-6 and TNF-α in patients with sepsis were
significantly lower than those of healthy control subjects.
Analysis of a subset of 15 patients after 7 days showed
an increase of intracellular cytokine levels. However,
they studied fewer patients than we did; they did not re-
port differences between survivors and non-survivors on
day 7; and their population comprised patients with in-
fections of mixed aetiology, including the respiratory
tract. The same group of researchers [11] focused on
serial changes of gene expression of PBMCs in a small
number of patients with sepsis developing in the field of
Fig. 4 TNF-α production by LPS-stimulated PBMCs as an index of sepsis-induced immunosuppression. a Comparative production of TNF-α by
PBMCs from healthy control subjects and patients after stimulation with LPS and Pam3Cys. The exact p values after correction for multiple testing
are provided: a9.8 × 10−4; b2.5 × 10−3; c7.6 × 10−4; d5.7 × 10−4; enon-significant. b ROC curve analysis to identify a cut-off concentration of TNF-α
produced by PBMCs after stimulation with LPS on day 3 between patients and healthy control subjects. c Survival analysis between patients with
production of TNF-α less than 250 pg/ml (defective, n = 42) and patients with production of TNF-α more than 250 pg/ml (adequate, n = 46).
p Values of significance are provided. LPS Lipopolysaccharide, PBMC Peripheral blood mononuclear cell, TNF-α Tumour necrosis factor-α
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community-acquired pneumonia. The level of expression
of genes encoding for cytokines involved in the inflam-
matory response, such as TNF, IL-6 and IL-8, was de-
creased on day 7 among non-survivors compared with
the first 48 h from organ dysfunction. This finding was
compatible with our observation of persistence of sepsis-
induced immunosuppression among non-survivors.
It should be emphasised that the enrolled studied
population had sepsis originating from gram-negative
bacteria (Table 1). Although gram-negative bacteria
carry a wide variety of pathogen-associated molecular
patterns (PAMPs) that can interact with Toll-like recep-
tors (TLRs) embedded on circulating monocytes and tis-
sue macrophages, their LPS is the best studied PAMP.
Exposure to LPS leads to endotoxin tolerance whereby a
second exposure to LPS elicits blurred cytokine produc-
tion [12–14]. Circulating PBMCs of both survivors and
non-survivors have defective cytokine production on day
1 after exposure to LPS, representing signs of LPS toler-
ance. LPS tolerance down-regulates the stimulatory effi-
cacy of other TLRs [15], and this can partly explain why
circulating PBMCs of patients did not respond to stimu-
lation with Pam3Cys, which is a purified ligand for TLR1
and TLR2. Owing to the interaction of TLR4 becoming
tolerant to LPS with the other TLRs making them toler-
ant to their ligands, it becomes evident that survivors of
our study escaped from tolerance to both TLR2 and
TLR4 as early as 48 h after the first blood sampling.
Two main limitations of our study should be under-
scored. The first limitation is related to the inability to
isolate the exact pathogen in all enrolled pathogens, rais-
ing concerns regarding whether the results may be gen-
eralisable to all patients with severe gram-negative
infections. However, the infections to be studied were
selected because they are caused mainly by gram-
negative bacteria [6], whereas the offending pathogen,
wherever isolated, was one gram-negative species. The
second limitation is the use of PBMCs that are a mixed
population of lymphocytes and monocytes; the lympho-
cyte/monocyte ratio may change over time, at least
Table 2 Univariate analysis of characteristics of 88 patients on admission with sepsis in relation to the effected tumour necrosis
factor-α production on day 3 by peripheral blood mononuclear cells after stimulation with bacterial lipopolysaccharide
TNF-α production ≤250 pg/ml
(n = 42)
TNF-α production >250 pg/ml
(n = 46)
p Value
Male sex, n (%) 16 (38.1) 26 (56.5) 0.093
Age, years mean ± SD 69.7 ± 12.2 69.6 ± 19.6 0.755
APACHE II score, mean ± SD 15.36 ± 8.13 11.63 ± 7.20 0.025
PaO2/FiO2, mmHg, mean ± SD 322.6 ± 150.5 302.5 ± 99.9 0.570
White blood cells, count/mm3, mean ± SD 13,735.0 ± 7725.3 15,007.2 ± 7102.4 0.418
Lymphocytes, count/mm3, mean ± SD) 1170.0 ± 697.2 1218.1 ± 644.2 0.805
C-reactive protein, mg/L, mean ± SD 152.2 ± 104.3 110.0 ± 90.6 0.135
Type of infection, n (%)
Acute pyelonephritis 17 (40.5) 23 (50.0) 0.399
Acute intra-abdominal infection 16 (38.1) 13 (28.3) 0.370
Gram-negative bacteraemia 9 (21.4) 10 (21.7) 0.901
Type of failing organ, n (%)
Acute respiratory distress syndrome 5 (10.9) 9 (21.4) 0.245
Acute coagulopathy 8 (17.4) 2 (4.8) 0.093
Acute kidney injury 5 (10.9) 4 (9.5) 1.000
Cardiovascular failure 1 (2.2) 9 (21.4) 0.006
At least one chronic disorder, n (%) 28 (66.7) 23 (50.0) 0.134
At least one predisposing condition, n (%) 15 (35.7) 24 (52.2) 0.138
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, PaO2/FiO2 Ratio of partial pressure arterial oxygen and fraction of inspired oxygen, TNF-α
Tumour necrosis factor-α
Table 3 Step-wise logistic regression analysis of patients’
characteristics on day 1 to predict sepsis-induced immuno-
suppression on day 3 as expressed by tumour necrosis
factor-α production less than 250 pg/ml after stimulation of
peripheral blood mononuclear cells with lipopolysaccharide
OR 95% CI p Value
Male sex a 0.099
Acute coagulopathy a 0.057
Cardiovascular failure 12.27 1.48–101.66 0.020
aThese two variables were excluded from the first step of the analysis as being
non-significant in the equation
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between baseline and day 7 [16], and this may hamper
precise interpretation of findings.
Our results encourage former attempts with the use
of immunostimulation to improve sepsis outcomes.
Recombinant human IFN-γ was the most common
approach, originating as an idea in the early 1980s [3].
Leentjens et al. [17] conducted a double-blind,
placebo-controlled, randomised study with healthy
volunteers becoming tolerant to LPS after the intra-
venous administration of LPS; subcutaneous treatment
with IFN-γ reversed LPS tolerance, as shown by increased
circulating TNF-α. Other proposed approaches targeting
reversal of immunoparalysis include GM-CSF administra-
tion [18], recombinant human IL-7 [19, 20] and the anti-
PD-1 antibody [21]. Proving the clinical efficacy of these
agents requires the conduct of randomised clinical trials
where patients most likely to jump into immunosuppres-
sion that does not resolve early should be enrolled. The
present study provides evidence that patients with CV fail-
ure on SIRS onset are most likely to have persistence of
sepsis-induced immunosuppression on day 3. These pa-
tients may be likely for inclusion in studies with agents
targeting reversal of immunosuppression.
Conclusions
The present study emphasises the association between
cytokine stimulation of circulating PBMCs and final out-
come. Sustained decreased cytokine production is linked
with great risk for unfavourable outcome, and it is a
characteristic of sepsis-induced immunosuppression. De-
fective production of TNF-α lasts as long as day 10, and
it is associated with greatest risk for unfavourable out-
come. CV failure on admission is a major indicator of
the likelihood for defective TNF-α responses over the
time course of sepsis. These findings can help in the de-
sign of future trials on immunostimulation for the man-
agement of severe sepsis.
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